121 related articles for article (PubMed ID: 11367165)
1. A tale of two trials of HAART interruption.
STEP Perspect; 1999; 99(1):7. PubMed ID: 11367165
[TBL] [Abstract][Full Text] [Related]
2. IL-2 plus HAART reduces HIV in immune system "hiding places".
WORLD; 1998 Dec; (No 92):7. PubMed ID: 11365976
[TBL] [Abstract][Full Text] [Related]
3. ICAAC and Hamburg: Part 3. Fruhlingstraum, or what it takes to mend an immune system.
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Jan; 4(1):12-25. PubMed ID: 11365028
[TBL] [Abstract][Full Text] [Related]
4. Restoring HIV-specific immunity.
James JS
AIDS Treat News; 1999 Feb; (No 312):2-6. PubMed ID: 11366200
[TBL] [Abstract][Full Text] [Related]
5. Immune control.
Fornataro K; Jefferys R
Body Posit; 1999 Mar; 12(3):9-12. PubMed ID: 11366299
[TBL] [Abstract][Full Text] [Related]
6. Remune trial ended.
Res Initiat Treat Action; 1999 Jul; 5(3):28. PubMed ID: 11366725
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 (IL-2): a path toward functional eradication?
Proj Inf Perspect; 1998 Dec; (26):20-1. PubMed ID: 11366494
[TBL] [Abstract][Full Text] [Related]
8. Investigational interleukins: the cutting edge of immune reconstitution.
Whitfield L
Posit Aware; 1998; 9(3):35-7. PubMed ID: 11365485
[TBL] [Abstract][Full Text] [Related]
9. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials.
Posit Aware; 1997; 8(5):24. PubMed ID: 11364635
[TBL] [Abstract][Full Text] [Related]
11. Honing the immune attack on HIV.
Gilden D
GMHC Treat Issues; 1996 Dec; 10(12):8-11. PubMed ID: 11364019
[TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 clinical trials.
Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495
[TBL] [Abstract][Full Text] [Related]
14. Open clinical trials for HIV/AIDS treatments.
Townley D
BETA; 1999 Apr; 12(2):53-6. PubMed ID: 11366699
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 for the treatment of HIV infection.
Simmons P
Res Initiat Treat Action; 1999 Apr; 5(2):17-21. PubMed ID: 11366280
[TBL] [Abstract][Full Text] [Related]
16. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
17. Light at the end of the tunnel?
STEP Perspect; 1999; 99(1):2. PubMed ID: 11367158
[TBL] [Abstract][Full Text] [Related]
18. Ich bin eine Berliner: the hope for remission of HIV.
Martinez LJ
Res Initiat Treat Action; 1999 Apr; 5(2):5-7. PubMed ID: 11366288
[TBL] [Abstract][Full Text] [Related]
19. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
20. High-dose IL-2 without HAART.
TreatmentUpdate; 1999 Mar; 11(2):3-4. PubMed ID: 11366776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
